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MicroRNA (miRNA) are small non-coding RNA molecules that posttranscriptionally effect
mRNA stability and translation by targeting the 3′-untranslated region (3′-UTR) of vari-
ous transcripts. Thus, dysregulation of miRNA affects a wide range of cellular processes
such as cell proliferation and differentiation involved in organ remodeling processes. Diver-
gent miRNA patterns were observed during chronic liver diseases of various etiologies.
Chronic liver diseases result in uncontrolled scar formation ending up in liver ﬁbrosis or
even cirrhosis. Since it has been shown that miR-29 dysregulation is involved in synthesis
of extracellular matrix proteins, miR-29 is of special interest. The importance of miR-29
in hepatic collagen homeostasis is underlined by in vivo data showing that experimental
severe ﬁbrosis is associated with a prominent miR-29 decrease.The loss of miR-29 is due
to the response of hepatic stellate cells to exposure to the proﬁbrogenic mediators TGF-β
and PDGF-BB. Several putative binding sites for the Smad proteins and the Ap1 complex
are located in the miR-29 promoter, which are suggested to mediate miR-29 decrease in
ﬁbrosis. Other miRNA are highly increased after proﬁbrogenic stimulation, such as miR-21.
miR-21 is transcriptionally upregulated in response to Smad-3 rather than Smad-2 activa-
tion after TGF-β stimulation. In addition, TGF-β promotes miR-21 expression by formation
of a microprocessor complex containing Smad proteins. Elevated miR-21 may then act as
a proﬁbrogenic miRNA by its repression of theTGF-β inhibitory Smad-7 protein.
Keywords: microRNA, fibrosis, extracellular matrix,TGF-β, PDGF, Smad proteins, Ap1
INTRODUCTION
Liver ﬁbrosis is characterized by excessive scarring, caused by
chronic inﬂammatory processes during liver diseases of differ-
ent origin. In response to chronic liver injuries, various cell types
get activated and transdifferentiate into myoﬁbroblastic cells that
then participate in synthesis and reorganization of connective tis-
sue (Hautekeete and Geerts, 1997; Friedman, 1999, 2008; Knittel
et al., 1999). A main source of extracellular matrix (ECM) produc-
tion are hepatic stellate cells (HSC) undergoing myoﬁbroblastic
transition (Hautekeete and Geerts, 1997; Friedman, 1999, 2008).
Myoﬁbroblastic differentiation and matrix accumulation of HSC
is heavily triggered by proﬁbrogenic mediators such as transform-
ing growth factor β (TGF-β) and the β-isoform of platelet-derived
growth factor (PDGF). Hence, in response to TGF-β, HSC take
center stage during ﬁbrosis by the enhanced synthesis of ECM pro-
teins, in particular collagen I and II. Here,we emphasize the role of
dysregulated microRNA (miRNA) during liver ﬁbrosis, their func-
tion in ECM expression and in proﬁbrogenic signaling in HSC.
DYSREGULATION OF miRNA IN LIVER FIBROSIS
The ﬁbrotic remodeling process and the change of gene expres-
sion during liver ﬁbrosis are associated with an altered pattern of
miRNA. miRNA are small (∼19–24 nucleotides long) non-coding
RNA molecules inhibiting posttranscriptionally gene expression.
It is suggested that more than one-third of all human genes
are regulated by miRNA (Krek et al., 2005; Lewis et al., 2005).
The primary miRNA (pri-miRNA) molecules of more than 1000
bases in length are transcribed by RNA-Polymerase II. Cleavage
of the pri-miRNA then generates the precursor miRNA (pre-
miRNA). This pre-miRNA is exported into the cytoplasm and
further processed by RNase III and Dicer resulting in the release
of a mature miRNA (Ruby et al., 2007). After integration into the
RNA-induced silencing complex (RISC), interaction of miRNA
sequences with the untranslated region (UTR) of transcripts
causes translational repression or transcript degradation (Bar-
tel, 2009). Several algorithms predict that one miRNA might
bind to a multitude of mRNA transcripts and, in turn, that one
mRNA might be targeted by a widespread panel of miRNA species
(Doench and Sharp, 2004; Lewis et al., 2005).
In liver, miR-122 is the most abundant miRNA, accounting for
more than 70% of the total miRNA in hepatocytes (Jopling et al.,
2005). miR-122 is involved in cholesterol synthesis and hepatitis
C virus (HCV) replication (Jopling et al., 2005; Esau et al., 2006).
After liver injury and ﬁbrosis it is markedly decreased depend-
ing on severity of ﬁbrosis (Cheung et al., 2008; Morita et al.,
2011). Other miRNA species, that are also highly expressed in
the healthy liver, e.g., miR-125b or miR-22, were shown to be
additionally reduced in ﬁbrotic liver biopsies of chronic hepatitis
C patients. Furthermore, the members of the miR-29 family, as
well as miR-194 and miR-150 are reported to be downregulated
during ﬁbrogenesis (Kwiecinski et al., 2011; Roderburg et al.,
2011). Additionally, miR-19b is recently found to be diminished
in ﬁbrotic liver of rat and human (Table 1) (Lakner et al., 2012).
Whereas a wide range of miRNA are reduced after ﬁbrosis, only
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Table 1 | Dysregulated miRNA during liver fibrosis and myofibroblastic HSC activation.
Upregulated
miRNA
Downregulated
miRNA
Etiology Reference In HSC under fibrotic
condition (Reference)
miR-122 Human NAFLD, NAFLD (HFD
rat, mice)
Alisi et al. (2010), Cheung et al.
(2008)
Guo et al. (2009a), Ji et al. (2009)#
miR-122 Chronic HCV hepatitis Morita et al. (2011)
miR-29a, -29b NAFLD, chronic HCV
hepatitis, CCl4 intoxication of
mice
Kwiecinski et al. (2010), Ogawa
et al. (2010), Roderburg et al. (2011)
Kwiecinski et al. (2011), Ogawa et al.
(2010), Roderburg et al. (2011)
CCl4 intoxication of mice,
NAFLD (HFD rat, mice),
chronic HCV hepatitis
miR-199a, -199a* Murakami et al. (2011)
miR-200a, -200b Alisi et al. (2010), Murakami et al.
(2011), Pogribny et al. (2010)
p.o.
miR-34a, -34b
Murakami et al. (2011), Pogribny
et al. (2010)
p.o.miR-146b
Murakami et al. (2011)
miR-150, miR-194 Venugopal et al. (2010)
miR-27a, -27b NAFLD (HFD rat) Alisi et al. (2010) Ji et al. (2009)
miR-15b, -16 Guo et al. (2009b), Guo et al. (2009c)
miR-132 Mann et al. (2010)
miR-335 Chen et al. (2011)
miR-19b Cholestasis (bile duct ligation) Lakner et al. (2012) Lakner et al. (2012)
p.o., Personal observation; NAFLD, non-alcoholic fatty liver disease; HFD, high fat diet.
#The miR-122 decrease, observed in primary HSC during culture-induced myoﬁbroblastic activation, might be due to the dilution of contaminating hepatocyte miRNA
of the primary HSC isolate.
some miRNA like the members of the miR-199, the miR-200, and
the miR-34 family are known to be increased (Alisi et al., 2010;
Pogribny et al., 2010; Murakami et al., 2011). Though miR-21
upregulation was only analyzed on ﬁbrotic liver biopsies of a lim-
ited number of HCVpatients (Marquez et al., 2010), inmany other
organs miR-21 is one of the most important miRNA prevalently
expressed after ﬁbrosis induction (Thum et al., 2008; Liu et al.,
2010; Zhu and Fan, 2011).
Recent reports have shown that altered miRNA levels are also
associated with the phenotypical changes of HSC during the
myoﬁbroblastic transitionprocess including the inductionof ECM
proteins (Guo et al., 2009a; Ji et al., 2009) (Table 1).
THE MEMBERS OF THE miR-29 FAMILY REPRESS
PROFIBROGENIC GENE EXPRESSION
The members of the miR-29 family are of particular interest
because they are shown to inhibit ECM synthesis indicating an
antiﬁbrotic function. ThemiR-29 family consists of miR-29a,miR-
29b, and miR-29c, differing only in two or three bases. miR-29a
and miR-29b1 as well as miR-29c and miR-29b2, are encoded and
transcribed in tandem by two genes located on chromosome 7
or chromosome 1, respectively (Mott et al., 2007; Wang et al.,
2008). van Rooij et al. (2008) ﬁrst reported the miR-29 function
after myocardial infarction. The authors proved miR-29 medi-
ated repression of elastin, collagen I and III synthesis in cardiac
ﬁbroblasts and its regulation by TGF-β. Accordingly, downregu-
lation of miR-29 was suggested to enhance the ﬁbrotic response
after myocardial infarction, whereas overexpression of miR-29 in
cardiac ﬁbroblasts reduced collagen expression. Similarly, Ogawa
et al. (2010) demonstrated that miR-29 inhibits the production of
ﬁbrillar collagen in HSC, suggesting also a function of miR-29 in
liver ﬁbrosis (Roderburg et al., 2011). Furthermore, highly con-
served binding sites for the miR-29a and miR-29b are found in
many 3′-UTR sequences of the various subunits of ECM proteins
like collagen type V and XV subunits, laminin γ 1, and nidogen.
The ﬁndings of Cushing et al. (2011) suggest that miR-29a and
miR-29b are also involved in a widespread panel of other ﬁbrosis
associated genes including Adam metalloproteinases mainly type
12 and 9, ECM formatting components such as ﬁbrillin-1 and
follistatin-1,anddifferent integrin chains. Recentworkof Kwiecin-
ski et al. (in review) showed that miR-29 not only targets gene
expression of ECM associated proteins, but also the expression of
proﬁbrogenic growth factors (manuscript submitted). They found
putativemiR-29a andmiR-29bbinding sites inmRNAof IGF-I but
most notably also in members of PDGF linked signaling pathways
such as PDGF-β receptor, PDGF-C, and VEGF-A. Accordingly,
miR-29 mediated inhibition of IGF-I and PDGF-C was proven in
HSC. In addition, Sekiya et al. (2011) collect evidence that also the
PDGF-β receptor is targeted by miR-29 regulation.
As a consequence, miR-29 acts as antiﬁbrogenic miRNA by
two pathways (1) by inhibition of ECM formation and (2) inter-
fering with the proﬁbrogenic cell communication pathways via
PDGF-B and PDGF-C signaling (Figure 1B). Interestingly, miR-
29 expression is in turn highly regulated by PDGF-BB (Ogawa
et al., 2010). Thus, the loss of miR-29 in myoﬁbroblastic HSC
during liver ﬁbrosis is mainly due to proﬁbrogenic stimulation by
TGF-β and PDGF-BB (Ogawa et al., 2010; Kwiecinski et al., 2011).
LOSS OF miR-29 IN THE FIBROTIC LIVER IS A RESULT OF
PROFIBROGENIC SIGNALING
The decrease of miR-29 was observed after experimental ﬁbro-
sis including liver intoxication in mice and cholestasis induced
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FIGURE 1 | miR-29 involved in profibrogenic signaling. (A) Genetic
structure and promoter region of the miR-29 members. The members of
the miR-29 family are encoded by two genes, located on chromosome 7
or 1, respectively. The pri-miR-29a and b1 as well as the miR-29c and b2 are
each transcribed in tandem. The mature miR-29 sequences differ only in
max. three bases, but sharing an identical seed region (yellow shadowed).
The promoter region of the miR-29a/b1 gene contains several putative
binding sites for the proﬁbrogenic repression of miR-29: three Ap1
consensus sequences (Ap1-RE), threeTGF-β inhibitory elements (TIE) and
in addition the three putative Smad binding elements (SBE). These
transcriptional binding sites and their interaction are suggested to mediate
proﬁbrogenic stimulation of PDGF-BB (i.p. of the Ap1 RE sites) and of
TGF-β by Smad and Ap1 signaling. (B) miR-29 signaling in the healthy and
the ﬁbrotic liver. In the healthy liver, mir-29 is highly expressed in hepatic
stellate cells (1) and is responsible for repression of extracellular matrix
proteins (ECM) in particular collagens (2), but also of expression of growth
factors such as PDGF-C and IGF-I. During ﬁbrogenesis, proﬁbrogenic
growth factors are increased and stimulate hepatic stellate cells in a
paracrine and autocrine manner (3). Proﬁbrogenic stimulation of TGF-β and
PDGF-BB results in miR-29 repression (4). The loss of miR-29 byTGF-β and
PDGF-BB results in the abolished repression of proﬁbrogenic expression
of ECM, PDGF-C or IGF-I (5). The enhanced secretion of PDGF-C and IGF-I
stimulates autocrinely stellate cells, leading to increased proliferation and
ECM production (6).
ﬁbrosis after bile duct occlusion in rat. Furthermore, in liver
biopsies of patients with chronic hepatitis C miR-29 levels are sig-
niﬁcantly reduced (Kwiecinski et al., 2011; Roderburg et al., 2011).
These in vivo studies suggest that the loss of miR-29 during liver
ﬁbrogenesis leads to the abolishment of ECM and proﬁbrogenic
mediator repression. The ﬁndings on HSC provide additional evi-
dence, that reduced miR-29 levels leading to proﬁbrogenic gene
expression are due to TGF-β or PDGF-BB exposure. The Smad-2/3
proteins act as the main signal transducers of TGF-β stimulation,
initiating ECM synthesis and myoﬁbroblastic transition (Dooley
et al., 2000, 2001a). In renal ﬁbrosis, silencing of the miR-29c/b2
gene is assumed to involve Smad-3 signaling (Qin et al., 2011).
However, the analysis of promoter regions of both miR-29 genes,
shown in Figure 1A, has just started by deﬁning the transcrip-
tional NF-KB and YY-NF-KB control, respectively (Wang et al.,
2008; Mott et al., 2010), and did not yet focus on TGF-β signaling.
Interestingly, the promoter sequence of the miR-29a/b1 gene
harbors several CAGA-boxes. CAGA-boxes function as Smad-
3/4 protein binding elements (SBE) and Smad-3/4 binding is
commonly followed by induction of gene transcription (Dennler
et al., 1998). However, suppressive effects of Smad proteins are
also possible, depending on their interaction with other regu-
latory factors like histone deacetylases (Liberati et al., 2001) or
the activator protein 1 (Ap1; Hall et al., 2003). Thus, TGF-β
induced Smad-3/4 signaling and the regulatory binding of the
SBE may contribute to the transcriptional repression of the miR-
29a/b1 gene. In addition, three consensus sequences for bind-
ing of the transcription factor Ap1 are located in the upstream
region of the miR-29a/b1 gene. Ap1 is highly activated by the
ras/raf pathway after TGF-β and PDGF-BB exposure (Angel and
Karin, 1992; Zhang et al., 1998). Ap1 interaction with the Ap1
responsive elements (Ap1 RE) drives transcription of a broad
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FIGURE 2 | Function of miR-21 in profibrogenicTGF-β signaling. During
ﬁbrosis TGF-β binds to the receptors leading to Smad-2 or Smad-3
phosphorylation, followed by aggregation with Smad-4 (1). The Smad-3/4 is
shown to induce transcriptional induction of synthesis of pri-miR-21 (2).
The further cleavage of pri-miRNA into hairpin-loop precursor miRNA is
catalyzed by the PDCD4/Drosha complex. The Smad proteins can interact
with the RNA helicase p68, which is integrated in the microprocessing
complex. After TGF-β exposure, both the Smad-2 and Smad-3 protein is
bound by p68 of the complex resulting in stabilization and high
microprocessing efﬁciency (3). High levels of miR-21 target the Smad-7
mRNA and repress translation of the inhibitory Smad-7 (4). The decrease
of the inhibitory Smad-7 protein in turn abolishes the negative feed-back
mechanisms of TGF-β signaling (5) resulting in elevated proﬁbrogenic TGF-β
stimulation.
spectrum of genes involved in the early gene response and acute
inﬂammatory stimulation. However, Ap1 can also function as
transcriptional suppressor by binding to TGF-β inhibitory ele-
ments (TIE), that are known to lead to gene silencing in the
stromelysin (Kerr et al., 1990), the HGF, and the c-myc gene
(Matrisian et al., 1992; Yagi et al., 2002). Thus, in future exper-
iments it has to be proven if proﬁbrogenic miR-29 repression is
mediated by the consensus sequences of the TIE, the Ap1 RE,
the SBE, or even by the interplay of different regulatory elements
(Figure 1A).
ENHANCED miR-21 LEVELS IN RESPONSE TO TGF-β BY
TRANSCRIPTIONAL INDUCTION AND PROMOTED
MICROPROCESSING
miR-21 is an ubiquitously expressed miRNA, which is highly
upregulated in the majority of cancer types. In cancer,miR-21 acts
as an oncogenic miRNA (oncomiR) targeting PTEN and other
tumor suppressor proteins (Krichevsky and Gabriely, 2009; Qi
et al., 2009). Previous reports have demonstrated that miR-21 is
also enhanced after initiation of myocardial, renal, or pulmonary
ﬁbrosis (Thum et al., 2008; Liu et al., 2010).
miR-21 enrichment during ﬁbrosis is assumed to be based
on proﬁbrogenic stimulation by TGF-β, because Zhong et al.
(2011) have demonstrated that Smad-3 transducing TGF-β
signaling, is crucial for miR-21 transcription. Furthermore, the
signal transducers of TGF-β, the receptor-regulated Smad-2 and
Smad-3 (R-Smad), are able to interact with the p68 RNA heli-
case of the Drosha/PDCD4 microprocessor complex, promot-
ing the restriction of pri-miR-21 into the precursor pre-miR-21
(Davis et al., 2008). Thus, the upregulation of miR-21 during
ﬁbrotic processes is based on two TGF-β stimulated mecha-
nisms, that are mediated by the Smad proteins: (1) by tran-
scriptional induction and (2) by enhanced miR-21 maturation
(Figure 2).
A potential mechanism for the role of miR-21 in ﬁbrosis is
through regulating the protein synthesis of the inhibitory Smad-7
(Figure 2; Liu et al., 2010; Marquez et al., 2010). Smad-7 mediates
a negative feed-back mechanism of TGF-β signaling. After TGF-
β stimulation, Smad-7 transcription is driven by Smad-2/3 and
Smad-4 (Stopa et al., 2000; Dooley et al., 2001b). Enhanced Smad-
7 levels, in turn, are highly potent to antagonize TGF-β-mediated
pathways (1) by blockade of the TGF-β type I receptor for fur-
ther binding of the receptor Smads (Massague and Chen, 2000),
and (2) by Smurf2 interaction, to form an E3 ubiquitin ligase that
targets the TGF-β type I receptor for degradation (Kavsak et al.,
2000).
Therefore, the inhibition of Smad-7 in response to miR-21
enhancement during ﬁbrosis has to be considered as an important
proﬁbrogenic pathway, which might become an attractive target
for future therapeutical approaches. In contrast to miR-21 that
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promotes TGF-β signaling, a recent study of Lakner et al. shows
that miR-19b which is downregulated during ﬁbrosis, inhibits
TGF-β pathways. miR-19b represses ﬁbrotic features after myoﬁ-
broblastic activation of stellate cells by targeting the TGF-β II
receptor and most notably Smad-3 (Lakner et al., 2012). Hence,
upcoming knowledge of miRNA species, involved in proﬁbrogenic
signaling, will provide novel perspectives in understanding and
probably also in treatment of chronic liver diseases.
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